R. Jt, W. H. Grf-r, R. Jt, W. H. Grf-r-were, ;. Jt et al., AD were involved in data interpretation. JT wrote the first draft of the report. All authors critically reviewed the manuscript for scientific content and approved the final version for submission. Declaration of interests JT reports no financial interests; she reports unremunerated participation in Roche, Celgene, Janssen, and Takeda advisory boards. SFB has received research funding from AstraZeneca

, MM has provided unremunerated consultancy for Roche Pharmaceuticals, and has received honoraria for lectures and preparation of educational materials from Roche China. CO has received honoraria from F Hoffmann, Roche Pharmaceuticals. DB has participated in advisory boards for Roche, Janssen-Cilag, and Gilead Sciences, and has received travel grants from Roche and Gilead Sciences

B. Janssen-cilag, F. Squibb, . Hoffmann-la-roche-;-celgene, . Gilead, . Takeda et al., JZ and DS are employed by F Hoffmann-La Roche. GRF-R and TN are employed by and own stock in F Hoffmann-La Roche. WH has received consultancy fees, research funding, and honoraria from F Hoffmann-La Roche, Janssen, and Gilead. REM has received research funding, travel support, and honoraria for advisory boards and lectures from F Hoffmann-La Roche. AD has received research support from Roche, AstraZeneca. VP has received honoraria from F Hoffmann-La Roche, and personal fees from Quintiles Eastern Holdings Gmb

R. Marcus, A. Davies, and K. Ando, Obinutuzumab for the first-line treatment of follicular lymphoma, N Engl J Med, vol.377, pp.1331-1375, 2017.

W. T. Swenson, J. E. Wooldridge, C. F. Lynch, V. L. Forman-hoffman, E. Chrischilles et al., Improved survival of follicular lymphoma patients in the United States, J Clin Oncol, vol.23, pp.5019-5045, 2005.

D. Tan, S. J. Horning, and R. T. Hoppe, Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience, Blood, vol.122, pp.981-87, 2013.

J. Trotman, M. Fournier, and T. Lamy, Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants, J Clin Oncol, vol.29, pp.3194-200, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00741692

J. Trotman, S. Luminari, and S. Bousetta, Prognostic value of PET-CT after firstline therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies, Lancet Haematol, vol.1, pp.17-27, 2014.

J. Dupuis, A. Berriolo-riedinger, and A. Julian, Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS, J Clin Oncol, vol.30, pp.4317-4339, 2012.

S. Luminari, I. Biasoli, and A. Versari, The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL), Ann Oncol, vol.25, pp.442-489, 2014.

S. F. Barrington, N. G. Mikhaeel, and L. Kostakoglu, Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group, J Clin Oncol, vol.32, pp.3048-58, 2014.

M. Meignan, A. Gallamini, and C. Haioun, Report on the first international workshop on interim-PET-scan in lymphoma, Leuk Lymphoma, vol.50, pp.1257-60, 2009.

C. Tychyj-pinel, R. F. Fulham, and M. , PET/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study, Eur J Nucl Med Mol Imaging, vol.41, pp.408-423, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01141154

B. D. Cheson, R. I. Fisher, and S. F. Barrington, Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification, J Clin Oncol, vol.32, pp.3059-68, 2014.

B. D. Cheson, B. Pfistner, and M. E. Juweid, Revised response criteria for malignant lymphoma, J Clin Oncol, vol.25, pp.579-86, 2007.

M. E. Juweid, S. Stroobants, and O. S. Hoekstra, Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma, J Clin Oncol, vol.25, pp.571-78, 2007.

B. D. Cheson, S. J. Horning, and B. Coiffier, Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group, J Clin Oncol, vol.17, p.1244, 1999.

J. R. Anderson, K. C. Cain, and R. D. Gelber, Analysis of survival by tumor response, J Clin Oncol, vol.1, pp.710-729, 1983.

W. Hiddemann, A. M. Barbui, and M. A. Canales, Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety, J Clin Oncol, vol.36, pp.2395-404, 2018.

G. A. Salles, J. F. Seymour, and P. Feugier, Long term follow-up of the PRIMA study: half of patients receiving rituximab maintenance remain progression free at 10 years, Blood, vol.130, issue.1, p.486, 2017.

Q. Shi, C. R. Flowers, and W. Hiddemann, Thirty-month complete response as a surrogate end point in first-line follicular lymphoma therapy: an individual patientlevel analysis of multiple randomized trials, J Clin Oncol, vol.35, pp.552-60, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01800000

C. Casulo, M. Byrtek, and K. L. Dawson, Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study, J Clin Oncol, vol.33, pp.2516-2538, 2015.

A. Launonen, W. Hiddemann, U. Duenzinger, G. Fingerle-rowson, T. Nielsen et al., Early disease progression predicts poorer survival in patients with follicular lymphoma (FL) in the GALLIUM study, Blood, vol.130, issue.1, p.1490, 2017.

C. Casulo, J. Le-rademacher, and J. Dixon, Validation of POD24 as a robust early clinical endpoint of poor survival in follicular lymphoma: results from the Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) investigation using individual data from 5453 patients on 13 clinical trials, Blood, vol.130, issue.1, p.412, 2017.

G. Gritti, C. Pavoni, and A. Rambaldi, Is there a role for minimal residual disease monitoring in follicular lymphoma in the chemo-immunotherapy era?, Meditter J Hematol Infect Dis, vol.9, p.2017010, 2017.

S. Luminari, S. Galimberti, and A. Versari, Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma: a subset analysis from the FOLL05 trial for the Fondazione Italiana Linfomi, Haematologica, vol.101, pp.66-68, 2016.

S. Galimberti, S. Luminari, and E. Ciabatti, Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial, Clin Cancer Res, vol.20, pp.6398-405, 2014.

J. Trotman, A. Davies, and W. Hiddemann, Relationship between MRD and PET responses and PFS in previously untreated follicular lymphoma in the GALLIUM trial. Abstract accepted for poster presentation at the ASCO Annual Meeting, J Clin Oncol, vol.36, p.7557, 2018.

M. Meignan, A. S. Cottereau, and A. Versari, Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies, J Clin Oncol, vol.34, pp.3616-3642, 2016.

L. Kostakoglu, A. Goy, and G. Martinelli, FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study, Leuk Lymphoma, vol.58, pp.372-81, 2017.

S. Herter, F. Herting, and O. Mundigl, Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models, Mol Cancer Ther, vol.12, pp.2031-2073, 2013.

E. Mössner, P. Brünker, and S. Moser, Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-medicated B-cell cytotoxicity, Blood, vol.115, pp.4393-402, 2010.